Skip to content

STOCK REPORT · LLY · NYSE

Eli Lilly and Company

Price$1,208.74+$42.23 · +3.62% ≈ ₩1,624,160
A

Overall grade

71 pointsUpper band

Overall 71 points · Grade A, 14 points to Grade S

Metrics with values 8 of 9 · Top 25.6% among graded major stocksThe other metric is not measured in this update, because the data has no such item.

Financial summary

Eli Lilly and Company (LLY) has an overall grade of A from financial statements, with a score of 71 out of 100. Category scores are Earnings 100 (Grade S), Financial health 44 (Grade C) and Dividends 63 (Grade B). Data as of Oct 15, 2026.

Reported figures: ROE 102.29%, Operating margin 54.22%, Revenue growth +47.7%, Debt ratio 162.07%, Current ratio 135.5%, Dividend yield 0.59%, Payout ratio 21.69%, Dividend streak 30+ yrs. Valuation: PER 39.16x, PBR 31.81x, Market cap $1.08T.

8 of the 9 graded metrics have values in this update.

This summary restates reported financial figures. It does not forecast share prices or returns.

Valuation

PER39.16x
PBR31.81x
Market cap$1.08T

52-week range

Now at 84% of range
$783.85$1,292.65
From high -6.5%From low +54.2%

Within their own 52-week ranges, 83.9% of major US stocks sit lower than this one.

About these metrics
PER
Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
PBR
Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
Market cap
Share price × shares outstanding. The value the market puts on the whole company.
52-week high
The highest share price over the past year.
52-week low
The lowest share price over the past year.

Scores by category

Each metric out of 100 · category score is the average of three
S

Earnings · Profitability

40% of overall · Top band
100 pts
ROE102.29%
Metric score 100 out of 100
Operating margin54.22%
Metric score 100 out of 100
Revenue growth+47.7%
Metric score 100 out of 100

Each metric is scored out of 100, and the 100 above is the average of the three scores.

Metrics with values3 of 3

As of Jun 2026

About these metrics
ROE
Return on equity. How much profit the company made on its own capital (equity).
Operating margin
Operating profit as a share of revenue. It shows the profitability of the core business.
Revenue growth
How much revenue changed compared with a year earlier.
C

Financial health

35% of overall · Lower-middle band
44 pts
Debt ratio162.07%
Metric score 27.6 out of 100
Current ratio135.5%
Metric score 54.7 out of 100
Interest coverageNot reported
Metric score 50 out of 100

Each metric is scored out of 100, and the 44 above is the average of the three scores.

Metrics with values2 of 3

Metrics shown as - in the table are not measured in this update, because the data has no such item.

About these metrics
Debt ratio
Liabilities as a share of equity. A lower ratio means the company relies less on debt.
Current ratio
Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
Interest coverage
How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.
B

Dividends

25% of overall · Middle band
63 pts
Dividend yield0.59%
Metric score 24.8 out of 100
Payout ratio21.69%
Metric score 66.7 out of 100
Dividend streak30+ yrs
Metric score 100 out of 100

Each metric is scored out of 100, and the 63 above is the average of the three scores.

Metrics with values3 of 3

About these metrics
Dividend yield
Dividends paid over a year as a share of the current share price.
Payout ratio
The share of profit paid out as dividends. A very high ratio can be hard to keep up.
Dividend streak
How many years in a row the company has paid a dividend.

Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.

Strengths · Weaknesses

Strengths

  • High profit relative to equity (ROE 102.29%)Above the median 13.5% of 37 Healthcare stocks
  • High profitability in the core business (operating margin 54.22%)Above the median 24.2% of 40 Healthcare stocks
  • Revenue is growing fast (+47.7% year on year)
  • Has paid dividends for 30+ yrs in a row

Weaknesses

  • Heavy debt burden (debt ratio 162.07%)Above the median 54.9% of 36 Healthcare stocks

A summary of only the metrics that stand out as notably good or weak against general benchmarks. Where a comparison is possible, the position against the median of stocks in the same sector is shown too. The stock count on each sector line covers only stocks with that metric, so it differs by metric.

Metrics that moved the overall score

Baseline 50 + 21.5 = 71.5 pts
  • ROE+6.7 pts
  • Operating margin+6.7 pts
  • Revenue growth+6.7 pts
  • Dividend streak+4.2 pts
  • Payout ratio+1.4 pts
  • Current ratio+0.5 pts
  • Interest coverage0.0 pts
  • Dividend yield-2.1 pts
  • Debt ratio-2.6 pts

Metric scores run up to 100, and the middle score is 50. If all nine metrics scored 50, the overall score would also be 50. Each bar is the contribution of one metric: how far its score sits from the 50 baseline, converted by that metric weight. Right means it raised the overall score, left means it lowered it.

Adding the nine contributions above to the baseline gives 71.5 points, and this stock's overall score is 71. The overall score is calculated from unrounded metric scores and then truncated, while the contributions here are rounded to one decimal place, so the two can differ by up to 1 point. Metrics that are not measured values still carry a contribution, because their scores did go into the overall score and hiding them would hide part of the basis of the grade.

Sector comparison

Healthcare · 40 stocks
MetricEli Lilly and CompanySector medianRank in sector
PER39.2x29.0x
PBR31.8x4.7x
ROE102.3%13.5%
Operating margin54.2%24.2%
Debt ratio162.1%54.9%
Dividend yield0.6%0.7%

Grey values on the right are sector medians

Metric ranks in sector

Closer to 1st sits further left
  • PERRank 26 of 33, top 79%
  • PBRRank 36 of 37, top 97%
  • ROERank 1 of 37, top 3%
  • Operating marginRank 1 of 40, top 3%
  • Debt ratioRank 33 of 36, top 92%
  • Dividend yieldRank 17 of 30, top 57%

On the rank strip, the left end is 1st. PER, PBR and debt ratio are ranked from the lowest value, and ROE, operating margin and dividend yield from the highest.

Sector medians cover the 40 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.

About these metrics
PER
Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
PBR
Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
ROE
Return on equity. How much profit the company made on its own capital (equity).
Operating margin
Operating profit as a share of revenue. It shows the profitability of the core business.
Debt ratio
Liabilities as a share of equity. A lower ratio means the company relies less on debt.
Dividend yield
Dividends paid over a year as a share of the current share price.

Where this score sits

74.4% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade A: 109.

  • S112.8%
  • AThis stock10927.3%
  • B19248.1%
  • C7117.8%
  • D164%

The Grade A band runs from 70 to 84 points, 15 points wide. This stock's 71 points sit 1 points above the lower boundary, and 14 points remain to 85, where Grade S starts.

Within the Healthcare sector alone, it ranks No. 12 of 40 stocks with an overall score, and the median overall score of the sector is 65.

Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.

Schedule

Next earnings releaseIn 14 days

Earnings release

A date announced by the company.

The day the company publishes quarterly or annual results. Only the release date is covered, not the results. Release times are not covered, so only the date (Korea time) is shown. After the release, metrics such as revenue growth are updated at the next data refresh.

Last ex-dividend date62 days ago
Last dividend payment date35 days ago

Dividend dates

Ex-dividend date
Shares acquired from this date do not carry the dividend for that period. From this date the shares trade without the right to it.
Payment date
The day the confirmed dividend reaches shareholder accounts. It comes weeks to months after the ex-dividend date, and Korean year-end dividends are set only after the shareholder meeting confirms them.

These are the announced ex-dividend and payment dates. The next period is not shown until its dates are set. Days remaining are counted in Korea time when the page was updated, so they can be off by about a day. The dates are copied as announced and can change. For the size of the dividend, see dividend yield. For information only. Not investment advice.

Stocks with similar score profiles

StockEarningsFinancial healthDividends
Eli Lilly and Company (LLY, this stock)1004463
BMastercard Incorporated944860
BHD HYUNDAI ELECTRIC CO.,LTD954758
BMarathon Petroleum Corporation914559
AGE Aerospace935262

Eli Lilly and Company (LLY) has category scores of Earnings 100 · Financial health 44 · Dividends 63. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 9 points.

The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.

Metrics to read together

Read one at a time, metrics split into strengths and weaknesses, but side by side two of them can be two sides of the same fact.

  • ROEDebt ratio

    High ROE sits on top of heavy debt

    ROE divides profit by equity, so it also rises when borrowing grows and equity gets thinner. Eli Lilly and Company has a high ROE of 102.29% and a heavy debt ratio of 162.07%. Read apart, one is a strength and the other a weakness, but these two figures alone cannot separate how much profit was made from how thin the equity is.

This explains how reported figures relate to each other. It says nothing about future results or share prices. Metrics without measured values are left out.

Ratios as amounts

Base ₩10,000

Every ratio metric of this stock, restated on the same amount. If each line used a different base, the amounts could not be compared, so every line starts from ₩10,000.

For every ₩10,000 of revenue: operating profit ₩5,420.Operating margin 54.2%

  • For every ₩10,000 of equityyearly net profit ₩10,230ROE 102.3%
  • If last year's revenue was ₩10,000this year's revenue ₩14,770Revenue growth 47.7%
  • For every ₩10,000 of equitydebt owed ₩16,210Debt ratio 162.1%
  • For every ₩10,000 of debt due within a yearassets turning into cash within a year ₩13,550Current ratio 135.5%
  • For every ₩10,000 worth of sharesdividends over the last year ₩60Dividend yield 0.6%
  • For every ₩10,000 of net profitdividends paid to shareholders ₩2,170Payout ratio 21.7%
  • For ₩10,000 of net profitmarket value ₩392,000PER 39.2x
  • For ₩10,000 of book equitymarket value ₩318,000PBR 31.8x

The ₩10,000 base is an assumption chosen for easy reading, not this company's actual revenue or equity. The values multiply the ratios shown as they are and round to the nearest won, so they can differ from the source by a few won. Metrics that make no sense as amounts are left out: values that are not measured, values that cannot be confirmed as measured, and loss-making cases where the base amount does not hold. This stock does not report in won, but ratios do not depend on currency, so the amounts are shown in won.

Metrics that decide the grade

Overall 71 · Grade A

The overall score recalculated with just one of the nine metrics set to the middle score of 50. Only one metric changes at a time, and the other eight stay as they are.

4 of the nine metrics would each take the overall score out of Grade A if only that metric were 50.

Overall score with only this metric at 50

  • ROEBgrade64.3 ptsEarnings · metric 100 · contribution +6.7
  • Operating marginBgrade64.3 ptsEarnings · metric 100 · contribution +6.7
  • Revenue growthBgrade64.3 ptsEarnings · metric 100 · contribution +6.7
  • Dividend streakBgrade66.8 ptsDividends · metric 100 · contribution +4.2

The scores above add up this stock's metric scores again with one of them set to 50. They are not new grades, and this stock's grade stays at A. Metric scores and contributions are rounded to one decimal place, so a change within 1 point of a boundary is not reported as a grade change. Changing two or more metrics at once was not calculated.

Where the share price enters the grade

The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.

1 of 9 graded metrics use the share price

1 of the 9 graded metrics divide by the share price.

  • Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
  • Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
  • Dividend grade metrics (3)Only Dividend yield divides by the share price1 of 3 metrics use the share price
  • PER and PBRCome from the share price but are not scoredNot graded

For US stocks, only Dividend yield divides dividends by the share price. It is recalculated when the price changes, and the other 8 metrics come from financial statements and dividend history.

Stocks with a value for each metric

The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.

8 of the 9 graded metrics have values.

  • ROEHas a value378 of 399 stocks have a value
  • Operating marginHas a value371 of 399 stocks have a value
  • Revenue growthHas a value375 of 399 stocks have a value
  • Debt ratioHas a value370 of 399 stocks have a value
  • Current ratioHas a value360 of 399 stocks have a value
  • Interest coverageNot reported190 of 399 stocks have a valueMore than half of stocks have no value
  • Dividend yieldHas a value352 of 399 stocks have a value
  • Payout ratioHas a value348 of 399 stocks have a value
  • Dividend streakHas a value398 of 399 stocks have a value

Blank metrics on this stock: 1. Many other stocks are blank on them too.

Position in the market distribution

US stocks

Where the value of Eli Lilly and Company sits when the US stocks on Jupick are lined up from the smallest value, ignoring sector. Left is smaller, right is larger, and the shaded part is the middle half.

The thin lower axis counts the position again within the same sector (Healthcare) only. 1 of the metrics with a lower axis sit in a different band from the whole market. On those lines, the bracket under the upper axis marks the middle half that the sector's stocks take on the market axis, and the short line inside is their middle.

  • PER39.2x
  • PBR31.8x
  • ROE102.3%
  • Operating margin54.2%
  • Debt ratio162.1%
  • Dividend yield0.6%On the upper axis, the middle half of these 24 stocks sits between 14.7% and 67.9%, with the middle at 31.9%.

Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample. The remaining sample size is shown on each line. The sector axis is not drawn when the same-currency, same-sector sample has fewer than 8 stocks.

In Korean won

Dollar amounts converted at the exchange rate below, to compare their size with Korean stocks in the same unit.

Price₩1,624,160$1,208.74
Market cap₩1,448T$1.08T
Exchange rate used$1 = ₩1,343.68as of Oct 15, 2026

Reference values calculated at the rate shown above. Actual trades and currency exchange use the rate and fees of the broker, so amounts differ. The 52-week high and low are not converted, because it is not known when they were set and so no rate can be chosen.

Korean and US yardsticks

Healthcare sector

Where one value of Eli Lilly and Company sits among US stocks in the same sector, and among Korean stocks. Only ratio metrics that compare across currencies are used.

1 of the 5 compared metrics sit in different bands on the two yardsticks.

  • PER 39.2x US 24 stocks · highest quarter · 79.2% have a smaller value Korean 9 stocks · upper middle · 66.7% have a smaller value Gap between yardsticks 12.5 pp

Only metrics with at least 8 stocks on both sides are compared.

Investment notice

For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.